# Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Phase III

> **NCT05096845** · PHASE3 · UNKNOWN · sponsor: **Livzon Pharmaceutical Group Inc.** · enrollment: 22500 (estimated)

## Conditions studied

- COVID-19 Pandemic

## Interventions

- **BIOLOGICAL:** Recombinant SARS-CoV-2 fusion protein vaccine (V-01)
- **OTHER:** Blank Preparation of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)

## Key facts

- **NCT ID:** NCT05096845
- **Lead sponsor:** Livzon Pharmaceutical Group Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-25
- **Primary completion:** 2022-02-08
- **Final completion:** 2023-06-14
- **Target enrollment:** 22500 (ESTIMATED)
- **Last updated:** 2023-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05096845

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05096845, "Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Phase III". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT05096845. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*